Integrated multi-omics reveals anaplerotic insufficiency in methylmalonyl-CoA mutase deficiency
Creators: name: Forny, Patrick
name: Bonilla Bustillo, Ximena
name: Lamparter, David
name: Shao, Wenguang
name: Plessl, Tanja
name: Frei, Caroline
name: Bingisser, Anna
name: Goetze, Sandra
name: van Drogen, Audrey
name: Harshman, Keith
name: Pedrioli, Patrick G.A.
name: Howald, Cedric
name: Poms, Martin
name: Traversi, Florian
name: Cherkaoui, Sarah
name: Morscher, Raphael J.
name: Simmons, Luke
name: Forny, Merima
name: Xenarios, Ioannis
name: Aebersold, Rudolf
name: Zamboni, Nicola
name: Rätsch, Gunnar
name: Dermitzakis, Emmanouil
name: Wollscheid, Bernd
name: Baumgartner, Matthias R.
name: Froese, D. Sean
Publisher: name: ETH Zurich
Year: 2022

description: Multi-layered omics approaches can help define relationships between genetic factors, biochemical processes and phenotypes thus extending research of inherited diseases beyond identifying their monogenic cause 1. We implemented a multi-layered omics approach for the inherited metabolic disorder methylmalonic aciduria (MMA). We performed whole genome sequencing, transcriptomic sequencing, and mass spectrometry-based proteotyping from matched primary fibroblast samples of 230 individuals (210 affected, 20 controls) and related the molecular data to 105 phenotypic features. Integrative analysis identified a molecular diagnosis for 84% (177/210) of affected individuals, the majority (148) of whom had pathogenic variants in methylmalonyl-CoA mutase (MMUT). Untargeted analysis of all three omics layers revealed dysregulation of the TCA cycle and surrounding metabolic pathways, a finding that was further corroborated by multi-organ metabolomics of a hemizygous Mmut mouse model. Integration of phenotypic disease severity indicated downregulation of oxoglutarate dehydrogenase and upregulation of glutamate dehydrogenase, two proteins involved in glutamine anaplerosis of the TCA cycle. The relevance of disturbances in this pathway was supported by metabolomics and isotope tracing studies which showed decreased glutamine-derived anaplerosis in MMA. We further identified MMUT to physically interact with both, oxoglutarate dehydrogenase complex components and glutamate dehydrogenase providing evidence for a multi-protein metabolon that orchestrates TCA cycle anaplerosis. This study emphasizes the utility of a multi-modal omics approach to investigate metabolic diseases and highlights glutamine anaplerosis as a potential therapeutic intervention point in MMA.Take home message Combination of integrative multi-omics technologies with clinical and biochemical features leads to an increased diagnostic rate compared to genome sequencing alone and identifies anaplerotic rewiring as a targetable feature of the rare inborn error of metabolism methylmalonic aciduria.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the ETH domain strategic focus area Personalized Health and Related Technology (PHRT; https://www.sfa-phrt.ch).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Canton of Zurich, Switzerland gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.
description: medRxiv